Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 1
1946 5
1948 2
1950 1
1951 1
1952 2
1953 1
1955 1
1956 3
1957 2
1958 1
1959 4
1960 1
1961 1
1962 1
1963 1
1964 1
1965 2
1967 1
1968 3
1969 4
1970 5
1971 2
1972 3
1973 2
1974 2
1975 4
1976 2
1977 3
1979 2
1984 1
1987 1
1988 2
1989 3
1990 4
1991 4
1992 3
1993 4
1994 4
1995 5
1996 6
1997 18
1998 8
1999 7
2000 24
2001 13
2002 30
2003 30
2004 32
2005 30
2006 18
2007 24
2008 25
2009 27
2010 30
2011 26
2012 38
2013 28
2014 29
2015 35
2016 48
2017 41
2018 46
2019 49
2020 44
2021 50
2022 51
2023 53
2024 34
2025 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

948 results

Results by year

Filters applied: . Clear all
Page 1
A single-cell survey of the small intestinal epithelium.
Haber AL, Biton M, Rogel N, Herbst RH, Shekhar K, Smillie C, Burgin G, Delorey TM, Howitt MR, Katz Y, Tirosh I, Beyaz S, Dionne D, Zhang M, Raychowdhury R, Garrett WS, Rozenblatt-Rosen O, Shi HN, Yilmaz O, Xavier RJ, Regev A. Haber AL, et al. Among authors: herbst rh. Nature. 2017 Nov 16;551(7680):333-339. doi: 10.1038/nature24489. Epub 2017 Nov 8. Nature. 2017. PMID: 29144463 Free PMC article.
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial.
Herbst RS, Wu YL, John T, Grohe C, Majem M, Wang J, Kato T, Goldman JW, Laktionov K, Kim SW, Yu CJ, Vu HV, Lu S, Lee KY, Mukhametshina G, Akewanlop C, de Marinis F, Bonanno L, Domine M, Shepherd FA, Urban D, Huang X, Bolanos A, Stachowiak M, Tsuboi M. Herbst RS, et al. J Clin Oncol. 2023 Apr 1;41(10):1830-1840. doi: 10.1200/JCO.22.02186. Epub 2023 Jan 31. J Clin Oncol. 2023. PMID: 36720083 Free PMC article. Clinical Trial.
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS; ADAURA Investigators. Wu YL, et al. Among authors: herbst rs. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi: 10.1056/NEJMoa2027071. Epub 2020 Sep 19. N Engl J Med. 2020. PMID: 32955177 Clinical Trial.
A cellular and spatial map of the choroid plexus across brain ventricles and ages.
Dani N, Herbst RH, McCabe C, Green GS, Kaiser K, Head JP, Cui J, Shipley FB, Jang A, Dionne D, Nguyen L, Rodman C, Riesenfeld SJ, Prochazka J, Prochazkova M, Sedlacek R, Zhang F, Bryja V, Rozenblatt-Rosen O, Habib N, Regev A, Lehtinen MK. Dani N, et al. Among authors: herbst rh. Cell. 2021 May 27;184(11):3056-3074.e21. doi: 10.1016/j.cell.2021.04.003. Epub 2021 Apr 30. Cell. 2021. PMID: 33932339 Free PMC article.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, Morise M, Felip E, Andric Z, Geater S, Özgüroğlu M, Zou W, Sandler A, Enquist I, Komatsubara K, Deng Y, Kuriki H, Wen X, McCleland M, Mocci S, Jassem J, Spigel DR. Herbst RS, et al. N Engl J Med. 2020 Oct 1;383(14):1328-1339. doi: 10.1056/NEJMoa1917346. N Engl J Med. 2020. PMID: 32997907 Clinical Trial.
Lung cancer.
Herbst RS, Heymach JV, Lippman SM. Herbst RS, et al. N Engl J Med. 2008 Sep 25;359(13):1367-80. doi: 10.1056/NEJMra0802714. N Engl J Med. 2008. PMID: 18815398 Free PMC article. Review. No abstract available.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. Among authors: herbst rs. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC.
Jassem J, de Marinis F, Giaccone G, Vergnenegre A, Barrios CH, Morise M, Felip E, Oprean C, Kim YC, Andric Z, Mocci S, Enquist I, Komatsubara K, McCleland M, Kuriki H, Villalobos M, Phan S, Spigel DR, Herbst RS. Jassem J, et al. Among authors: herbst rs. J Thorac Oncol. 2021 Nov;16(11):1872-1882. doi: 10.1016/j.jtho.2021.06.019. Epub 2021 Jul 12. J Thorac Oncol. 2021. PMID: 34265434 Free article. Clinical Trial.
948 results